Skip to Content

Do you allow analytics?

We use analytics tools to understand how people use the site. They're optional: if you decline, the site works the same, no analytics cookies are set and Google gets only a cookieless, anonymous count signal. Your votes are saved either way; the details are in the privacy policy.

Referandom is here: Tinder for Congress 🔥

Support Referandom
HealthH.R. 1672Not Yet VotedComments

Maintaining Investments in New Innovation Act

Official title: To amend title XI of the Social Security Act to protect access to genetically targeted technologies.

What Do You Think?

How would you vote?

Referandom Vote

Vote to see the result.

How Congress Voted

What Happened in Congress?

Pending

Not yet voted on the floor.

Where the Bill Stands

  1. Introduced, done
  2. Committee, current stage
  3. Floor Vote, not yet
  4. Outcome, not yet

What This Bill Does

This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)

Sponsors

Related Documents

Bill on Congress.govWeb Page ↗ (opens in a new tab)

Timeline

  1. Library of CongressIntroduced in House
  2. House floor actionsReferred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  3. Introduced
  4. Committee

Comments

Comments with insults, hate speech or personal information are removed.